Today, Monday, the Russian Direct Investment Fund announced that the Ministry of Health in the State of Palestine has registered the Russian vaccine against the Coronavirus “Sputnik V”.
Registration was carried out under the emergency license without conducting additional clinical trials on the country’s territory, after a similar procedure was evaluated, previously registered in Argentina, Bolivia, Serbia and Algeria.
Sputnik V is scheduled to be delivered to Palestine in the first quarter of this year.
The CEO of the Russian Direct Investment Fund, Kirill Dmitriev, said, “The high quality and effectiveness of the Sputnik V vaccine is attracting increasing interest from an increasing number of countries, indicating that this will” expand the geography of its registration, supply and production. “
Dmitriev added, “After Europe, Asia, Latin America and Africa, Sputnik V will be used in the Middle East as well. This also helps unite our efforts to achieve an early joint victory over the Coronavirus infection by facilitating access to an effective and safe vaccine for more countries and their populations.”
He explained that the registration of the “Sputnik V” vaccine came as a result of its main advantages, which are “more than 90% effectiveness, and the vaccine provides complete protection against severe cases of Corona virus disease.”
He stressed that “the Sputnik V vaccine was produced on the basis of a well-proven and studied platform of human adenovirus vectors, which cause colds and that humanity has faced thousands of years ago.”
He pointed out that “Sputnik V” uses two different types of vectors for two doses during the vaccination process, which creates stronger immunity compared to vaccines that use the same delivery mechanism for both doses.
“The safety, efficacy and reduction of long-term negative effects of adenovirus vaccines have been proven in more than 250 clinical studies over two decades,” he said.
The CEO of the Russian Direct Investment Fund confirmed that more than 1.5 million people have already been vaccinated, “Sputnik V”.
He referred to the cooperation of the producers and developers of the “Sputnik V” and “AstraZeneca” vaccine in clinical trials to improve the effectiveness of the British AstraZeneca vaccine.
Sputnik V has been approved in Russia, Belarus, Serbia, Argentina, Bolivia and Algeria, and the European Union vaccine registration process has begun.